Project to evaluate repurposing drugs to treat COVID-19
The Food and Drug Administration has partnered with the Critical Path Institute and National Center for Advancing Translational Sciences to launch the CURE Drug Repurposing Collaboratory, a forum for exchanging clinical practice data to inform potential new uses for existing drugs to treat unmet medical needs, beginning with COVID-19.
CDRC will use data collected via the CURE ID platform to aggregate global clinician treatment experiences and identify existing drugs that demonstrate possible treatment approaches warranting further study.
Related News Articles
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…